Bank of Montreal
TGTX icon

Bank of Montreal’s TG Therapeutics TGTX Stock Holding History

Bank of Montreal’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-65,000
Closed -$1.17M – 4241
2024
Q1 		$1.17M Buy
+65,000
New +$1.04M ﹤0.01% 1919

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Bank of Montreal's TGTX Position: Q2 2026 in Review

Bank of Montreal increased its TG Therapeutics (TGTX) stake by 0.13% in Q2 2026, buying an estimated $26.7K and bringing the position to 515,981 shares worth $28.3M. The position accounts for 0.01% of the portfolio, ranked #783.

Bank of Montreal first reported a position in TGTX in Q1 2014 and has held it in 36 quarters since. 279 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Bank of Montreal held 515,981 shares of TG Therapeutics worth $28.3M as of Q2 2026.
  • Bank of Montreal bought 653 TG Therapeutics shares in Q2 2026, an estimated $26.7K.
  • TG Therapeutics made up 0.01% of Bank of Montreal's portfolio in Q2 2026, its #783 holding.
  • Bank of Montreal first reported a position in TG Therapeutics in Q1 2014 and has held it in 36 quarters since.
  • 279 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.